DOWNSTREAM PROCESSING FEATURED ARTICLES
Novavax, Inc. (Nasdaq:NVAX) today announced that the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) has completed an In-Process Review (IPR) of Novavax' contract covering the company's recombinant virus-like particle (VLP) vaccine candidates for pandemic and seasonal influenza.
-
RNA-Based Therapy Brings New Hope For An Incurable Blood Cancer
Three thousand new cases of Mantle Cell Lymphoma (MCL), a form of blood cancer, appear in the United States each year. With a median survival span of only five to seven years, according to the Leukemia and Lymphoma Society, this disease is devastating, and new therapies are sorely needed.
-
NeoStem's Subsidiary, Progenitor Cell Therapy, Enters Into A Cell Therapy Manufacturing Services Agreement With Adaptimmune
NeoStem, Inc. and its subsidiary, Progenitor Cell Therapy LLC ("PCT"), together with Adaptimmune Limited and Adaptimmune LLC (collectively, "Adaptimmune"), announced recently a Services Agreement under which PCT will provide services to support Adaptimmune's NYESO-1c259-T cell therapy product being developed for multiple oncology indications (for more information with respect to Adaptimmune's clinical trials, see clinicaltrials.gov, identifiers NCT01350401, NCT01343043 and NCT01352286).
-
Studies Put Kibosh On Statins For Breast Cancer Prevention
New data from the Women’s Health Initiative dash cold water on the idea that statin therapy reduces breast cancer risk.The updated WHI findings showed no association between prior statin use and breast cancer risk in nearly 155,000 postmenopausal study participants followed prospectively for an average of 10.8 years.
DOWNSTREAM PROCESSING WHITE PAPERS & CASE STUDIES
-
An Automated Profiling Application For G9a Histone Methyltransferase And Bromodomain Proteins
Due to several findings, G9a and BET bromodomain proteins have become the target for numberous drug discovery projects. In this study, we describe a novel, cell-based assay platform that uses the robust, yet simple Enzyme Fragment Complementation (EFC) Technology.
-
Materials Of Construction For Biopharmaceutical Water Systems
Stainless steels are uniquely qualified for bioprocessing applications not only because of their long service life, availability, and fabricability, but also because they are non-corroding, non-contaminant, can be polished to very smooth finishes, are strong and rigid, can withstand heat and chemical sterilization treatments, and are easily welded. By Michelle M. Gonzalez
-
Automation Of A Homogeneous Proximity Assay For Detection Of Residual Protein A In Biological Therapeutics
Protein A is used in affinity chromatography for therapeutic antibody purification and has been shown to leach from columns during purification of antibodies resulting in contamination. Residual Protein A in therapeutic drugs could elicit mitogenic or immunological reactions in patients.
-
Biomanufacturing Flexibility
This white paper from BIO-G looks at how to create flexible, agile manufacturing facilities to respond to the current glut of biomanufacturing capacity and industry consolidation. Future proofing these facilities for higher titers and multiple product lines is also explored.
-
Biomanufacturing Supply Chains
This white paper examines the major issues with biopharmaceutical supply chains and how to balance inventory and risk optimally in the network.
-
Global Biochemical Profiling For Bioprocess Optimization
It is widely understood that the production phase of bioprocessing can have a significant impact on the overall profitability of the biopharmaceutical.